Topics

Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Lymphoma, Mantle-Cell,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 21/10/2014, Revision: 16, Status: Authorised

12:30 EST 4 Nov 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Lymphoma, Mantle-Cell,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 21/10/2014, Revision: 16, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Lymphoma, Mantle-Cell,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 21/10/2014, Revision: 16, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Lymphoma, Mantle-Cell,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 21/10/2014, Revision: 16, Status: Authorised"

Quick Search